150 Recruiting Chronic Lymphocytic Leukemia Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by State
Browse by Study Phase
Top Interventions for Chronic Lymphocytic Leukemia
Related Conditions
Top Recruiting Chronic Lymphocytic Leukemia Studies
Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia
📍 Mayo Clinic in Rochester — Rochester, Minnesota
View Study & Checklist ➔A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
📍 Alaska Oncology and Hematology ( Site 0037) — Anchorage, Alaska
View Study & Checklist ➔Economic Analysis of Alliance A041202 CLL Study
📍 Tom Baker Cancer Centre — Calgary, Alberta
View Study & Checklist ➔A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
📍 Research Site — Chandler, Arizona
View Study & Checklist ➔Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
📍 Research Site — Phoenix, Arizona
View Study & Checklist ➔A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL
📍 Beth Isreal Deaconess Medical Center — Boston, Massachusetts
View Study & Checklist ➔Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
📍 Research Site — Los Angeles, California
View Study & Checklist ➔Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
View Study & Checklist ➔Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
📍 Southern Cancer Center, P.C. — Daphne, Alabama
View Study & Checklist ➔Safe Accelerated Venetoclax Escalation in CLL
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
View Study & Checklist ➔Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)
📍 Icahn School of Medicine at Mount Sinai — New York, New York
View Study & Checklist ➔Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
📍 Research Site — Goodyear, Arizona
View Study & Checklist ➔A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
📍 Massachusetts General Hospital — Boston, Massachusetts
View Study & Checklist ➔A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
📍 University of Miami Sylvester Comprehensive Cancer Center — Coral Gables, Florida
View Study & Checklist ➔A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
📍 Ironwood Physicians, Ironwood Cancer and Research Centers — Chandler, Arizona
View Study & Checklist ➔Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
View Study & Checklist ➔A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
📍 Research Site — Tucson, Arizona
View Study & Checklist ➔ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
📍 Research Site — Boston, Massachusetts
View Study & Checklist ➔A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
📍 California Research Institute — Los Angeles, California
View Study & Checklist ➔Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib
📍 UC San Diego Moores Cancer Center — La Jolla, California
View Study & Checklist ➔huCART19-IL18 in CD19+ Cancers
📍 University of Pennsylvania — Philadelphia, Pennsylvania
View Study & Checklist ➔A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
📍 City of Hope /ID# 253904 — Duarte, California
View Study & Checklist ➔Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia
📍 Research Site — Columbus, Ohio
View Study & Checklist ➔An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
📍 University of Arizona Cancer Center - Tucson /ID# 210548 — Tucson, Arizona
View Study & Checklist ➔A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
📍 Highlands Oncology Group ( Site 5205) — Springdale, Arkansas
View Study & Checklist ➔A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
📍 Augusta University — Augusta, Georgia
View Study & Checklist ➔Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
View Study & Checklist ➔Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
📍 University of Miami- Sylvester Comprehensive Cancer Center — Miami, Florida
View Study & Checklist ➔Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔HEALTH4CLL2: A Randomized Waitlist Control Trial of Behavioral Interventions in Patients With Chronic Lymphocytic Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL
📍 Dana Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔